American Healthcare REIT (AHR) Q4 2025 earnings review
Operating Leverage in RIDEA Segments Overpowers Massive Equity Dilution
American Healthcare REIT (AHR) finished a phenomenal FY25, delivering 14.2% Total Portfolio Same-Store NOI growth and driving Normalized FFO per share up 22% to $1.72. The story is dominated by the massive operational leverage in its senior housing operating properties (SHOP) and integrated senior health campuses (ISHC). Management has matched this operational inflection with an aggressive external growth strategy, funding over $950 million in 2025 acquisitions heavily through forward equity and ATM issuances. Despite increasing the diluted share count from roughly 130 million to over 185 million, the deals are highly accretive. The balance sheet is the strongest it has been in years (3.4x Net Debt-to-EBITDA). However, guidance suggests the blistering pace of organic growth is naturally decelerating as comps get tougher.
🐂 Bull Case
The SHOP and ISHC segments continue to post incredible numbers, with Q4 Same-Store NOI growth of 24.6% and 14.0% respectively. Occupancies across these operating portfolios remain above 89% on average, providing exceptional pricing power.
AHR dramatically reduced its Net Debt-to-Annualized Adjusted EBITDA from 8.5x at the end of 2023 to just 3.4x at the end of 2025. This was achieved via prudent ATM equity issuance, eliminating debt overhang risks and providing immense dry powder for future acquisitions.
🐻 Bear Case
The 11.8% Q4 Total SS NOI growth represents a deceleration from the 14.2% full-year 2025 average and the 21.6% posted in Q4 2024. Furthermore, FY26 guidance projects further deceleration to 7.0%-11.0%.
The Outpatient Medical (OM) and Triple-Net Leased segments continue to act as an anchor on overall portfolio performance. Q4 SS NOI for OM grew just 2.2%, while Triple-Net grew only 1.8%. FY26 guidance projects these to grow at a sluggish 1.0% and 2.5%, respectively.
⚖️ Verdict: 🟢
Bullish. The sheer magnitude of the margin expansion in the SHOP and ISHC segments proves that AHR has successfully capitalized on the senior housing macro tailwinds. They have essentially solved their historical balance sheet issues while managing to make the massive equity dilution accretive to FFO.
Key Themes
Secular Demographic Tailwinds Fueling Pricing Power
Management continues to underscore the 'best operating environment' in decades, driven by a profound macro supply-demand imbalance. The 80+ population cohort is surging, while new senior housing construction starts remain near historic lows. This allows AHR to push rates—evidenced by the SHOP segment's RevPOR growth reaching $5,438 in Q4, driving Q4 SHOP margins to a robust 21.8%.
Accretive External Growth via Strategic Partnerships
AHR deployed over $950 million in 2025 across its ISHC and SHOP segments, capitalizing on strategic, off-market relationships with regional operating partners like Great Lakes Management and WellQuest Living. The company fully match-funded these acquisitions using its ATM program and forward equity offerings, locking in the spread between their cost of capital and the mid-7% to 8% target stabilized yields on acquired assets.
Leveraging Trilogy's Revenue Management Technology
AHR is actively taking the sophisticated, centralized revenue management software and practices developed by its premier operator, Trilogy Management Services, and rolling them out to its other independent regional operators. This technology-driven operational cross-pollination is a unique platform advantage designed to drive margin expansion outside of the core ISHC portfolio.
Medicare Rate Headwinds Require Mix-Shift Execution
Base national Medicare rates are seeing slower growth (approx. 3.2%) compared to the roughly 6% increases seen in prior years. To combat this headwind in the skilled nursing segment, Trilogy is relying on optimizing its quality mix by shifting beds toward higher-paying Medicare Advantage plans. While successful so far (Quality Mix reached 77.8% in Q4), relying on continuous mix-shift to outrun slower base rate growth carries execution risk.
Chronic Drag from the Outpatient Medical (OM) Portfolio
The OM segment is a glaring laggard in an otherwise high-growth portfolio. Delivering just 2.2% SS NOI growth in Q4 and guiding for 1.0% growth in FY26, the segment suffers from hospital system downsizing and tenant expirations. Although management has actively pruned the portfolio, it still represents approximately 15% of Annualized Cash NOI and materially dilutes the top-line growth generated by the RIDEA segments.
Other KPIs
Accelerating improvement. This marks a dramatic deleveraging from 3.5x at the end of 25Q3, 4.5x in 25Q1, and 8.5x at the end of 2023. AHR has successfully repaired its balance sheet by heavily utilizing its ATM program to match-fund acquisitions and clear expensive debt, providing them with over $1.14 billion in total liquidity.
Accelerating. The SHOP segment has expanded its margin by 289 basis points YoY (from 18.9% in 24Q4). This margin expansion is the pure result of operational leverage—occupancy has crossed into the low 90s, allowing revenue growth (+8.1% YoY) to significantly outpace controllable expense growth (+5.4% YoY).
AHR issued 6.47M shares via forward settlement ($275.1M) and an additional 659K shares via direct ATM ($32.5M). Furthermore, they locked in new forward agreements for another $808.8M (7.45M shares + 9.31M follow-on shares). While highly dilutive to the absolute share count, the company is issuing at premiums to NAV, immediately accretive to NFFO per share.
Guidance
Accelerating. The midpoint of $2.02 represents a strong 17.4% YoY growth rate over FY25's $1.72. This indicates management's confidence that their massive pipeline of 2025 acquisitions will yield highly accretive returns in their first full year of operations.
Decelerating. After posting an explosive 14.2% in FY25, growth is reverting toward a more normalized but still highly attractive high-single-digit rate. This reflects the reality of tougher YoY comps as occupancy levels in the SHOP and ISHC segments stabilize near peak levels.
Decelerating from FY25's record 25.2% growth. At 90.6% occupancy, the "easy" occupancy gains are largely behind the company. The 17.0% midpoint suggests growth will now primarily rely on pushing RevPOR above inflation and further leveraging Trilogy's revenue management tools.
Key Questions
Margin Ceilings in SHOP
With SHOP spot occupancy now exceeding 90% and Same-Store margins reaching 21.8%, what is the stabilized margin ceiling for this portfolio, and how much of the FY26 SHOP guidance relies on pure rate increases versus further occupancy gains?
Limits to Equity Issuance
The company has essentially match-funded $950M in acquisitions with over $1B in equity capital arrangements. At what point does the sheer volume of shares outstanding begin to weigh on the stock's technical performance, and is there a target leverage floor below the current 3.4x?
Outpatient Medical Strategy
With OM guidance remaining anemic at 0-2% growth and the segment serving as a clear drag on the explosive RIDEA growth, what is the trigger point for a complete divestiture of the remaining ~70 OM properties?
Execution Risk on New Operators
You added major new operators like Great Lakes Management and WellQuest Living in 2025. Given the complexities of rolling out the Trilogy revenue management systems, what early friction points are you seeing in integrating these independent operators into your centralized data ecosystem?